Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
24.6.2021
0:00
13:01
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
Weitere Episoden von „JAMA Oncology Author Interviews“
Verpasse keine Episode von “JAMA Oncology Author Interviews” und abonniere ihn in der kostenlosen GetPodcast App.